Universal Ibogaine Inc

FRA:JC4 (Canada)  
€ 0.00 (-77.5%) May 24
At Loss
P/B:
1.67
Market Cap:
€ 2.94M ($ 3.19M)
Enterprise V:
€ 4.58M ($ 4.97M)
Volume:
1.45K
Avg Vol (2M):
7.65K
Also Trade In:

Business Description

Description
Universal Ibogaine Inc develops a platform of addiction treatment clinics, which use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants. It runs addiction clinics it has a research partner clinic in Mexico.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.13
Equity-to-Asset 0.31
Debt-to-Equity 1.59
Debt-to-EBITDA -3.97
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -6.04
Distress
Grey
Safe
Beneish M-Score -0.92
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -26
3-Year EPS without NRI Growth Rate -21.6
3-Year FCF Growth Rate 7.2

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 44.97
9-Day RSI 47.16
14-Day RSI 47.88
6-1 Month Momentum % 350
12-1 Month Momentum % -18.18

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.5
Quick Ratio 0.5
Cash Ratio 0.31
Days Sales Outstanding 38.34

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -158
Shareholder Yield % -26

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -35.9
Net Margin % -53.35
FCF Margin % -20.84
ROE % -59.32
ROA % -20.8
ROIC % -12.8
ROC (Joel Greenblatt) % -27.95
ROCE % -26.64

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 1.36
PB Ratio 1.67
EV-to-EBIT -6.59
EV-to-EBITDA -9.66
EV-to-Revenue 3.06
EV-to-FCF -14.68
Earnings Yield (Greenblatt) % -15.17
FCF Yield % -10.6

Financials

FRA:JC4's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Universal Ibogaine Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 1.521
EPS (TTM) (€) -0.004
Beta 0
Volatility % 949.36
14-Day RSI 47.88
14-Day ATR (€) 0.00527
20-Day SMA (€) 0.0064
12-1 Month Momentum % -18.18
52-Week Range (€) 0.0005 - 0.0245
Shares Outstanding (Mil) 291.07

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Universal Ibogaine Inc Filings

Filing Date Document Date Form
No Filing Data

Universal Ibogaine Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Universal Ibogaine Inc Frequently Asked Questions

What is Universal Ibogaine Inc(FRA:JC4)'s stock price today?
The current price of FRA:JC4 is €0.00. The 52 week high of FRA:JC4 is €0.02 and 52 week low is €0.00.
When is next earnings date of Universal Ibogaine Inc(FRA:JC4)?
The next earnings date of Universal Ibogaine Inc(FRA:JC4) is .
Does Universal Ibogaine Inc(FRA:JC4) pay dividends? If so, how much?
Universal Ibogaine Inc(FRA:JC4) does not pay dividend.

Press Release

Subject Date
No Press Release